Send me real-time posts from this site at my email

Why Abiomed Stock Soared Today

What happened

Shares of Abiomed (NASDAQ: ABMD) were soaring 13.8% higher as of 3:26 p.m. EDT on Thursday. The big jump came after the medical device maker announced its fiscal 2020 fourth-quarter and full-year results before the market opened.

Abiomed reported Q4 revenue of $206.7 million, down slightly year over year and narrowly missing the consensus Wall Street revenue estimate of $207.2 million. However, the company's Q4 adjusted earnings per share of $1 easily topped the average analysts' adjusted earnings estimate of $0.94 per share.

So what

When a company reports mixed results as Abiomed did, investors usually don't get very excited. However, there were a couple of factors at play for the company that helped make its results look more encouraging than they otherwise would have.

Image source: Getty Images.

First, Abiomed was beginning to see positive momentum for its Impella heart pumps throughout much of the first quarter even with two publications that the company called misleading negatively weighing on sales. Those publications especially impacted Impella revenue in the U.S. and in Germany.

Second, the COVID-19 pandemic caused patient utilization to plunge in the second half of March. Investors realized, though, that the negative impact of the pandemic should be only temporary. Abiomed has taken several actions to reduce its expenses in the meantime, including placing a freeze on hiring; eliminating non-critical consultants, contractors, and temporary staff; and temporarily cutting executive salaries.

Now what

Abiomed CEO Michael Minogue said that the company "will endure the challenges and come out stronger as Abiomed 2.0." However, the healthcare stock could experience higher volatility than normal for the next months. The company didn't provide full-year guidance because of the uncertainties stemming from the COVID-19 pandemic.

On Wednesday, Abiomed announced that it acquired Breethe, a developer of an extracorporeal membrane oxygenation (ECMO) system that complements the company's existing product lineup. Breethe currently awaits FDA clearance of its ECMO system. The deal could boost Abiomed's sales when Breethe's devices are cleared for commercialization.

10 stocks we like better than Abiomed
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now… and Abiomed wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

*Stock Advisor returns as of April 16, 2020

Keith Speights has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Abiomed. The Motley Fool has a disclosure policy.


Popular posts

Welcome! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue